Nephrologist Barbara Murphy Dies at 56

Her work led to more predictable outcomes for kidney transplants.

Written byLisa Winter
| 2 min read
Barbara Murphy wearing a white lab coat, facing the camera with a blue background

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © MOUNT SINAI HEALTH SYSTEM

Barbara Murphy, a nephrologist who found new techniques for predicting kidney transplant outcomes, died on June 30 at the age of 56. The New York Times reports that Murphy’s husband, Peter Fogarty, confirmed glioblastoma as the cause of death.

Born in Ireland on October 15, 1964, Murphy attended medical school at the Royal College of Surgeons in Dublin, graduating in 1989. She remained in the city for an internship and fellowship at Beaumont Hospital, where she focused on clinical nephrology. She then moved to the United States for a nephrology postdoc position at Harvard University.

In 1997, she began working at Mount Sinai Health Systems in New York City as the director of transplant nephrology at the Icahn School of Medicine. In 2003, she became chief of the nephrology division. Within a decade, she had accepted a position as the director of the school’s ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies